BGPT: Author Review: Kaibo Guo

Explore by Goal

Quick Explanation Copied

Kaibo Guo — scientific strength (critical, evidence-weighted)

Based on the papers explicitly provided here, Guo’s publication record appears concentrated in oncology/clinical outcome studies and mechanistic reviews, including CRC prognostic/predictive analyses and EMT/resveratrol and other cancer-adjacent reviews. Evidence quality and rigor can’t be judged from metadata alone; a deeper review would require full texts to check design, bias control, effect sizes, and data transparency. See cited paper-by-paper evidence below.

Long Explanation

Author Review: Kaibo Guo (science-strength audit)

Date context: April 29, 2026 • Evidence scope: only the specific works and metadata explicitly included in your prompt.

Evidence landscape (based only on listed works)

Citation metrics (what we can & cannot verify here)

The prompt includes OpenAlex-style metrics (works count, cited_by_count, h-index) for “Kaibo Guo”. However, those figures are not accompanied by DOI-level sources in your input, so I’m not able to inline-cite them in the citation-only format you required. Therefore, the scientific-strength evaluation below focuses on the provided DOI-indexed works themselves, not the metric aggregates.

Provided works: paper-by-paper evidence anchors

Year	Type (from metadata)	Title	Core claim (what the paper sets out to do)
2021	Systematic review / meta-analysis (as labeled)	Robotic versus laparoscopic hepatectomy for malignancy: A systematic review and meta-analysis	Compares safety/efficacy of robotic vs laparoscopic hepatectomy for malignancy using meta-analytic synthesis.
2020	Original article (predictors)	Risk factors and predictors of lymph nodes metastasis and distant metastasis in newly diagnosed T1 colorectal cancer	Identifies clinicopathological factors associated with nodal and distant metastasis in T1 CRC, with prognostic/prediction modeling intent.
2019	Original article (prognostic factor)	Value of Tumor Size as a Prognostic Factor In Metastatic Colorectal Cancer Patients After Chemotherapy: A Population-Based Study	Evaluates tumor size as a prognostic factor in metastatic CRC after chemotherapy, using a population-based approach.
2021	Review (network pharmacology + meta-analysis approach)	Network Pharmacology Analysis to Explore the Pharmacological Mechanism of Effective Chinese Medicines in Treating Metastatic Colorectal Cancer using Meta-Analysis Approach	Integrates network pharmacology and meta-analysis logic to propose mechanisms via hub targets/pathways.
2020	Original article (microbiota associations)	Characteristics and differences of gut microbiota in patients with different Traditional Chinese Medicine Syndromes of Colorectal Cancer and normal population	Assesses gut microbiota differences between CRC patients categorized by TCM syndromes and normal controls.
2021	Original article (epidemiology outcomes)	Causes of Death After Colorectal Cancer Diagnosis: A Population-Based Study	Studies cause-specific mortality after CRC diagnosis, emphasizing non-cancer causes too.
2021	Review (mechanistic topic)	Resveratrol and Its Analogs: Potent Agents to Reverse Epithelial-to-Mesenchymal Transition in Tumors	Reviews resveratrol analogs as EMT inhibitors and potential adjuncts for metastasis-related processes.
2023	Review	Mesenchymal stem cell-derived exosomes as delivery vehicles for non-coding RNAs in lung diseases	Reviews MSC-derived exosomes as delivery vehicles for non-coding RNAs in lung diseases.

Scientific strength signals (and what’s missing)

1) Domain fit: oncology + translational biology themes

The provided works cluster around colorectal cancer clinical prediction/prognosis (predictors, tumor size prognostic effect, death causes) and mechanistic/biological review topics (EMT/resveratrol; exosomes/ncRNA delivery). For example, the CRC T1 metastasis-predictor study explicitly targets risk/predictor identification (). The EMT/resveratrol review frames a mechanistic rationale centered on reversing EMT and improving anticancer effects ().

2) Evidence-grade heterogeneity: models & observational signals vs synthesis & mechanistic review

Not all outputs have the same causal evidentiary strength. Observational prognostic/predictive studies and population-based analyses can be useful for risk stratification but are vulnerable to confounding (e.g., staging, treatment heterogeneity, selection bias). Mechanistic reviews compile reported pathways but may vary widely in how comprehensively they assess evidence quality. Example review framing includes network pharmacology logic for metastatic CRC () and CRC gut microbiota syndrome differences ().

3) Systematic-review evidence exists in the provided list (but needs full-text bias audit)

One of the explicitly listed works is a systematic review/meta-analysis comparing robotic vs laparoscopic hepatectomy for malignancy (). For rigor scoring, full-text would be needed to verify:

whether PRISMA-style search strategy and study selection are comprehensive,
how risk of bias is assessed in included surgical trials,
heterogeneity handling and publication bias assessment,
and how outcome definitions are standardized.

Those details are not present in your prompt, so I can’t confirm rigor from metadata alone.

Critical blindspots to check in a full-text audit

Confounding & selection bias in population-based CRC prognosis/predictor work (e.g., stage and treatment differences) — requires methods sections and covariate lists.
Microbiome analysis pitfalls (batch effects, sequencing depth normalization, compositionality, multiple testing) — requires full analytical pipeline details ().
Mechanistic review overreach: EMT/resveratrol and exosome/ncRNA reviews can rationally connect pathways but still require careful separation of preclinical vs clinical evidence (; ).
Reproducibility: network pharmacology/meta-analysis hybrids and mechanistic pathway summaries often depend on curated databases and analysis choices; full-text should confirm transparency of selection criteria and thresholds ().

What information would most change my judgment?

If full texts show strong prospective validation, robust external cohorts, transparent model calibration/decision-curve metrics, then prognostic/predictive papers would score higher.
If systematic-review full text shows low risk of bias, good search completeness, and consistent outcome definitions, then the meta-analysis signal would strengthen.
If reviews clearly quantify evidence grade (preclinical vs clinical; effect sizes; confidence) rather than relying on narrative pathway links, then mechanistic-review credibility increases.

Without full text, this review stays intentionally conservative.

Next step recommendation (for maximal rigor)

Click the BGPT “Author Review (full-text audit)” button at the top to retrieve and verify full methodological details (risk of bias, covariates, statistical reporting, reproducibility statements) rather than relying on abstracts/metadata.

Feedback:

Updated: April 29, 2026